You are here

Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
MHAT "Dr. Tota Venkova"AD
Gabrovo, , 5300 Bulgaria
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Anemia, Pregnancy, Lactation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients currently under treatment with Retacrit™ (epoetin zeta) administered
subcutaneously for renal anaemia.

- Informed consent given in writing after being provided with detailed information about
the characteristics of this observation by the physician.

- Patients expected to be available for 3 years of observation

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any contraindications as per the current Summary of Product Characteristics (SPC) of
Retacrit?

NCT01543477
Pfizer
Active, not recruiting
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now